Summary The monoclonal antibody 3F8 has been described as binding to the ganglioside GD2. This antibody, of the IgG3 isotype, has been used in immunotherapy, radioimmunolocalisation and targeted radiation therapy. 3F8 was originally observed to have a binding profile similar to two monoclonal antibodies, UJ13A and 5.1 HI 1, characterised as binding to the neural cell adhesion molecule (NCAM). This observation has also been confirmed using a hetero-antiserum prepared against purified NCAM. The cross-reactivity of 3F8 with NCAM has been confirmed by cross-blocking studies with an anti-NCAM antiserum, and by direct immunoprecipitation and gel electrophoresis. In addition, we show that 3F8 binds to human NCAM from 3T3 fibroblasts transfected with NCAM cDNA constructs. It is possible that the common epitope shared by GD2 ganglioside and NCAM involves sialic acid residues common to both the ganglioside and the glycoprotein.
Monoclonal antibodies have been widely employed in the search for tumour associated antigens. Many of these reagents have been shown to react with carbohydrate moieties associated with glycoproteins and/or glycolipids (Magnani, 1984; Feizi, 1985; Feizi & Childs, 1985) . Gangliosides, in particular, appear to be particularly good markers for neuroectodermal tumours. GD2 for example is present on human brain, but found in much higher amounts on melanoma and neuroblastoma tissues (Cahan et al., 1982; Schultz et al., 1984) . Antibodies such as 3F8, recognised the GD2 ganglioside Saito et al., 1985) , have been used for radioimmunoscintigraphy studies (Cheung et al., 1986; Miraldi et al., 1986) , and phase 1 clinical trials (Cheung et al., 1987) . Melanoma and neuroblastoma patients have been given 3F8, either alone or conjugated to 131I and some clinical responses have been noted.
We became particularly interested in the expression of GD2 as detected by monoclonal antibody 3F8, when it became apparent that the staining pattern of the antibody was similar to monoclonal antibodies UJ13A and 5.1.H11 (Kemshead, 1988) recently identified as binding to the neural cell adhesion molecule (NCAM) (Patel et al., 1989a, b) . In fact, a variety of monoclonal antibodies to GD2 have been shown to interfere with neuroblastoma and melanoma cell attachment to various substrate adhesive proteins (Cheresh et al., 1986) . Cheresh et al. (1986) suggest that GD2 and GD3 play a role in cell adhesion, excluding the possiblity that the reagents studied are binding to glycoproteins.
We report here (FCS) (Gibco), 2mM glutamine (Gibco), 100 IU ml-' penicillin (Gibco) and 100 fg ml-' streptomycin (Gibco) (complete medium). Cells were harvested in their exponential growth phase for subsequent studies. 3T3 fibroblasts transfected with human NCAM cDNA were grown as described previously (Gower et al., 1988) .
Antibodies and indirect immunofluorescence Monoclonal antibody 3F8 was raised following immunisation of mice with neuroblastoma cells . Two preparations of antibody were used for these studies. One was a purified fraction of ascites and the other concentrated tissue culture supernatant from the hydridoma. Monoclonal antibodies Thy-l (Cotmore et al., 1981) , UJ13A (Allan et al., 1983) and 5.1 .H11 (Hurko & Walsh, 1983) , were supplied as purified antibodies from tissue culture supernatant (ICRF central antibody service laboratory). The hetero-antiserum to NCAM was raised by hyperimmunisation of rabbits with purified mouse muscle NCAM (Moore et al., 1987 (Gower et al., 1988 antigen (Thy-1) present on the JR1 cell line. In a further series of blocking experiments we have confirmed that the epitopes present on NCAM that are recognised by UJ13A,. 5.1.H1l, ERIC-1 and 3F8 are distinct (Patel et al., 1989a) .
Biochemical characterisation of the binding of monoclonal antibody, 3F8 to either neuroblastoma or rhabdomyosarcoma cell lines As has been previously reported, monoclonal antibody 3F8 binds to the ganglioside GD2 . This we have confirmed following chloroform:methanol:water extraction of glycolipids from rhabdomyosarcoma cells, thin layer chromatography, immunoblotting with 1251 labelled 3F8 antibody and autoradiography (data not presented).
To determine if the epitope recognised by 3F8 involves sialic acid sugar moieties, JR1 cells were treated with neuraminidase. This reduced the level of radiolabelled antibody 3F8 (from culture supernatant) binding to 20% of the control as determined in a radiobinding assay. In contrast, no dimunition of monoclonal antibody 5.1 .H11 binding to JRI cells was observed after a similar treatment of cells with neuraminidase (Figure 2 ).
Surface labelling of either the SK-N-SH or JRI cells with 15I using the lactoperoxidase technique (Marchalonis et al., 1971) , cell lysis in extraction buffer (0.1 M Tris'CI pH 7.4 containing 0.9% NaCl, 0.5% Nonidet P-40, 2 mM phenyl methyl sulphonylfluoride), centrifugation ( x 100,000 g for 30min) and immuno-precipitation (Kemshead et al., 1983) did not result in the identification of any glycoprotein binding to monoclonal antibody 3F8. A similar result was found after Western blotting cell extracts (either NP40 or SDS extracts) of either neuroblastoma or rhabdomyosarcoma cells. However, after metabolically labelling neuroblastoma cells with 35S methionine and immunoprecipitation with 3F8, two major bands could be identified at 145 and 65 kDa along with an occasional weak band at 120 kDa (Figure 3) . The 145 and 120 kDa bands correspond to two of the isoforms of NCAM often reported after immunoprecipitation with the relevant antisera. Similar bands of 145 and 65 kDa were In contrast to this, no bands at these molecular weights were identified using either a control monoclonal antibody (anti-Thy) known to bind to the human homologue of the Thy-I antigen (Cotmore et al., 1981) or a non-immune rabbit antiserum.
Reactivity of 3F8 and 3T3 fibroblasts tran.sfected with human NCAM cDNA cDNA clones corresponding to the full coding sequence of various NCAM isoforms from human muscle have recently been isolated and placed in appropriate expression vectors (Gower et al., 1988) . Subsequently, the cDNAs have been transfected into 3T3 fibroblasts and permanei obtained. One of these (called G4) which synth kDa NCAM isoform (Gower et al., 1988) (Gower et al., 1988) . NCAM could be immunc from the G4 transfectants using an anti-hun antiserum. When this material was subsequen blotted protein bands of 110 and 125 kDa could following incubation of the blots with the antiserum (Figure 4a) (Cunningham et al., 1983; Finne anti-mouse et al., 1983) e Method)).
Cheresh et al. (1986) (Hoffman et al., 1982) . The 145 kDa and 120 kDa bands correspond to two of the three isoforms of NCAM (reviewed by Cunningham et al., 1987 (Patel et al., 1989a) . The glycosylation pattern of the transfected protein is not fully understood although the lack of binding of a monoclonal antibody to alpha 2-8 polysialic acid chains (greater than eight residues) would suggest that this modification does not take place in 3T3 cells. The fact that all three isoforms of NCAM are not detected by monoclonal antibody 3F8 in JRI cell extracts might reflect differential glycosylation of the three isoforms. Alternatively, it is known that the 145 kDa form of NCAM is the earliest isoform expressed during embryogenesis (Levi et al., 1987) and it is therefore, not surprising that the 145 kDa isoform is predominantly detected in a primitive embryonic tumour such as rhabdomyosarcoma. Northern blot analysis of RNa extract from the SK-N-SH neuroblastoma and JRl rhabdomyosarcoma cell line would suggest that this is the case as a 6.7 kb mRNA representing the 145 kDa protein (Dickson et al., 1987; Santoni et al., 1987; Small et al., 1987) is detected with a human NCAM cDNA probe. In contrast, cell lines which were negative for monoclonal antibody 3F8 and anti-NCAM antiserum staining did not contain NCAM mRNA as detected by Northern blot analysis (data not presented).
Other monoclonal antibodies which cross-react with NCAM have been described. One of the best characterised is the HNK-1 antibody (Abo & Balch, 1981) . This antibody appears to recognise a sulphated carbohydrate (Chou et al., 1985 (Chou et al., , 1987 Shashoua et al., 1986 ) present on a number of molecules involved in adhesion, including NCAM (Kruse et al., 1984 (Kruse et al., , 1985 McGarry et al., 1983) . The HNK-1 determinant is present on only 15-20% of all NCAM molecules (Kruse et al., 1984) . The epitopes recognised by monoclonal antibodies 3F8 and HNK-1 are different since, in an international workshop on neuroblastoma, there was considerable difference in the staining profiles of the two antibodies (Kemshead, 1988) . Furthermore, the HNK-1 epitope differs from that recognised by 3F8 in that it has been reported as not involving neuraminic acid (Chou et al., 1985) .
In conclusion, we have evidence that monoclonal antibody 3F8 reacts with NCAM in addition to its reactivity against GD2. Since monoclonal antibody 3F8 has been used for clinical trials on the basis that it was reactive against only GD2, its binding specificity needs to be re-examined. Crossreactions should not necessarily deter the use of reagents such as monoclonal antibody 3F8 for clinical purposes, but it will be necessary to evaluate them fully so that accurate binding profiles, affinity constants and antigen densities can be compared and contrasted.
